NAS:SBBP (USA) Also trade in: Germany

Strongbridge Biopharma PLC

$ 2.95 -0.08 (-2.64%)
Volume: 30,419 Avg Vol (1m): 245,270
Market Cap $: 164.14 Mil Enterprise Value $: 59.84 Mil
P/E (TTM): 9.47 P/B: 1.69
Earnings Power Value 1.03
Net Current Asset Value 1.08
Tangible Book 1.12
Projected FCF 0
Median P/S Value 9.53
Graham Number 2.84
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked lower than
79.41% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
SBBP: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.85, Med: 10000, Max: 10000
Current: 10000
0.85
10000
Equity-to-Asset 0.63
Equity-to-Asset ranked lower than
92.14% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
SBBP: 0.63
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.21, Med: 0.03, Max: 0.66
Current: 0.63
-0.21
0.66
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.64
DISTRESS
GREY
SAFE
Beneish M-Score -1.86
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 4.95%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -446.06
Operating Margin ranked lower than
70.33% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
SBBP: -446.06
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -752.47, Med: -603.46, Max: -454.45
Current: -446.06
-752.47
-454.45
Net Margin % 227.79
Net Margin ranked lower than
71.59% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
SBBP: 227.79
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1610.6, Med: -716.96, Max: 176.68
Current: 227.79
-1610.6
176.68
ROE % 98.28
ROE ranked lower than
100.00% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
SBBP: 98.28
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -412.23, Med: -57.3, Max: 63.05
Current: 98.28
-412.23
63.05
ROA % 26.86
ROA ranked lower than
73.89% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
SBBP: 26.86
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -94, Med: -41.6, Max: 23.23
Current: 26.86
-94
23.23
ROC (Joel Greenblatt) % 21898.76
ROC (Joel Greenblatt) ranked lower than
96.72% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
SBBP: 21898.76
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -536995, Med: -121986.31, Max: 29062.78
Current: 21898.76
-536995
29062.78

» SBBP's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SBBP

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare NAS:KALA OTCPK:ABVC NAS:CDMO NAS:KOD NAS:HARP NAS:EVLO LSE:ARIX LSE:BVXP NAS:DOVA NAS:MRNS NAS:MTEM XKRX:087010 XPAR:ALPHA WAR:SLV WAR:MAB NAS:VRCA NAS:CDXC NAS:ACRS TSE:2183 BOM:512529
Traded in other countries 69BN.Germany
Address 900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 9.47
PE Ratio ranked lower than
100.00% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
SBBP: 9.47
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 9.47, Med: 15.28, Max: 16.97
Current: 9.47
9.47
16.97
PE Ratio without NRI 9.47
PE without NRI ranked lower than
100.00% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
SBBP: 9.47
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 9.47, Med: 15.28, Max: 16.97
Current: 9.47
9.47
16.97
Price-to-Owner-Earnings 4.08
Price-to-Owner-Earnings ranked lower than
100.00% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
SBBP: 4.08
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 4.08, Med: 6.87, Max: 7.7
Current: 4.08
4.08
7.7
PB Ratio 1.69
PB Ratio ranked lower than
95.95% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
SBBP: 1.69
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.69, Med: 24.51, Max: 215.85
Current: 1.69
1.69
215.85
PS Ratio 8.35
PS Ratio ranked lower than
60.19% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
SBBP: 8.35
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 8.35, Med: 26.26, Max: 166.28
Current: 8.35
8.35
166.28
EV-to-EBIT 1.13
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
SBBP: 1.13
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -5.2, Med: -2.7, Max: 3.6
Current: 1.13
-5.2
3.6
EV-to-EBITDA 1.00
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
SBBP: 1
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -5.9, Med: -2.8, Max: 3.2
Current: 1
-5.9
3.2
EV-to-Revenue 3.23
EV-to-Revenue ranked lower than
57.33% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
SBBP: 3.23
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 3.2, Med: 27.7, Max: 155.3
Current: 3.23
3.2
155.3
Current Ratio 5.15
Current Ratio ranked higher than
63.31% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
SBBP: 5.15
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.38, Med: 6.46, Max: 10.23
Current: 5.15
3.38
10.23
Quick Ratio 4.96
Quick Ratio ranked higher than
63.78% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
SBBP: 4.96
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.11, Med: 6.38, Max: 10.23
Current: 4.96
3.11
10.23
Days Inventory 304.86
Days Inventory ranked lower than
53.85% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
SBBP: 304.86
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 62.88, Med: 133.47, Max: 204.06
Current: 304.86
62.88
204.06
Days Sales Outstanding 77.26
Days Sales Outstanding ranked higher than
51.20% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
SBBP: 77.26
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 32.92, Med: 57.49, Max: 82.06
Current: 77.26
32.92
82.06
Days Payable 661.98
Days Payable ranked higher than
88.06% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
SBBP: 661.98
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 108.42, Med: 207.67, Max: 306.92
Current: 661.98
108.42
306.92

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -32.80
3-Year Share Buyback Rate ranked lower than
79.46% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
SBBP: -32.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -37.3, Med: -32.8, Max: -31.6
Current: -32.8
-37.3
-31.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.70
Price-to-Tangible-Book ranked lower than
100.00% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
SBBP: 2.7
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.71, Med: 3.18, Max: 5.09
Current: 2.7
2.71
5.09
Price-to-Median-PS-Value 0.32
Price-to-Median-PS-Value ranked higher than
75.37% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
SBBP: 0.32
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.46, Med: 0.96, Max: 6.27
Current: 0.32
0.46
6.27
Price-to-Graham-Number 1.06
Price-to-Graham-Number ranked lower than
100.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
SBBP: 1.06
Ranked among companies with meaningful Price-to-Graham-Number only.
N/A
Earnings Yield (Joel Greenblatt) % 88.50
Earnings Yield (Greenblatt) ranked lower than
76.69% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
SBBP: 88.5
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -69.2, Med: -31.7, Max: 88.6
Current: 88.5
-69.2
88.6

More Statistics

Revenue (TTM) (Mil) $ 18.5
EPS (TTM) $ 0.32
Beta -0.75
Volatility % 55.67
52-Week Range $ 3 - 7.85
Shares Outstanding (Mil) 54.17

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y